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The triggering receptor expressed on myeloid cells (TREM) family of protein receptors is
rapidly emerging as a critical regulator of a diverse array of cellular functions, including
amplification of inflammation. Although the ligand(s) for TREM have not yet been
fully identified, circumstantial evidence indicates that danger- and pathogen-associated
molecular patterns (DAMPs and PAMPs) can induce cytokine production via TREM-1
activation. The discovery of novel functions of TREM, such as regulation of T-cell
proliferation and activation of antigen-presenting cells, suggests a larger role of TREM
proteins in modulation of host immune responses to microbial pathogens, such as bacteria
and fungi. However, the significance of TREM signaling in innate immunity to virus
infections and the underlying mechanisms remain largely unclear. The nature and intensity
of innate immune responses, specifically production of type I interferon and inflammatory
cytokines is a crucial event in dictating recovery vs. adverse outcomes from virus
infections. In this review, we highlight the emerging roles of TREM-1, including synergy
with classical pathogen recognition receptors. Based on the literature using viral PAMPs
and other infectious disease models, we further discuss how TREM-1 may influence
host-virus interactions and viral pathogenesis. A deeper conceptual understanding of the
mechanisms associated with pathogenic and/or protective functions of TREM-1 in antiviral
immunity is essential to develop novel therapeutic strategies for the control of virus
infection by modulating innate immune signaling.
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INTRODUCTION
The robust induction of innate immunity is the first line of
defense against virus infections and depends on the ability of the
host immune cells to detect invading pathogens and alert adap-
tive immune cells. Viral pathogens and replicative intermediates
present pathogen-associatedmolecular patterns (PAMPs), such as
viral double-stranded (ds) RNA, uncapped single-stranded (ss)
RNA and viral proteins, which are detected by pattern recognition
receptors (PRRs) expressed on immune cells. Typically, binding
of virus PAMPs to PRRs namely Toll-like receptors (TLRs), RIG-
I-like receptors (RLRs) and NOD-like receptors (NLRs) cause
activation of downstream signaling resulting in the production of
antiviral type I interferon (IFN) and pro-inflammatory cytokines
(Kumar et al., 2011). A timely production of IFN-α/β and pro-
inflammatory cytokines is critical for the clearance of the virus
during early phase of the infection and fine-tuning the innate-
adaptive interface for long-lasting protection. The activation of
these PRRs is very tightly regulated at multiple steps to prevent
tissue damage due to uncontrolled production of cytokines. Thus,
overall virus disease outcome depends on the magnitude and the
nature of innate immune events triggered following virus entry.
Understanding the host factors that participate in positive or neg-
ative regulation of innate immunity to virus infections is currently
the focus of intense research to seek out cues for designing thera-
peutics to modulate inflammation at the molecular level. Several
novel innate immunemolecules, including members of triggering
receptors expressed on myeloid cells (TREM) family of recep-
tors, have been recently characterized to play an important role
in modulating the intensity of innate immune responses.
Since the discovery of TREM in 2000, they have been described
as critical immunomodulators in several inflammatory disor-
ders of both infectious and non-infectious etiology (Ford and
McVicar, 2009). TREM-1 is the most well-characterized member
of the TREM family and plays an important role in the ampli-
fication of inflammation, crosstalk with other PRR pathways
and activation of antigen-presenting cells (APC). A substantial
amount of data supports the link between TREM-1 signaling and
several diseases, such as polymicrobial septic shock and inflam-
matory bowel disease, and in animal models of pneumonia and
asthma (Ford and McVicar, 2009; Klesney-Tait et al., 2012).
Although the data on the functions of TREM-1 in virus infec-
tions is limited, in vitro studies using viral PAMPs suggest the
ability of viruses to modulate TREM signaling. In this review, we
first discuss the current understanding of the immunoregulatory
functions of the TREM family, in particular TREM-1, and then
highlight potential roles of TREM-1 in antiviral immunity.
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TREM FAMILY OF RECEPTORS
Members of the TREM family (designated TREM-1 to TREM-4)
belong to the immunoglobulin variable (IgV) domain receptor
superfamily of proteins (Bouchon et al., 2000). They are cell sur-
face activating receptors with a transmembrane region containing
charged lysine residues and a short cytoplasmic tail lacking signal-
ing motifs (Bouchon et al., 2000). Signaling through these recep-
tors is facilitated by the adaptor protein DNAX-activating protein
of 12 kDa (DAP12) (Bouchon et al., 2000). TREM-1 was desig-
nated as CD354 by the Ninth Workshop on Human Leukocyte
Differentiation Antigens in 2011 (Matesanz-Isabel et al., 2011).
The human TREM family members, which share low sequence
homology with each other, are located on chromosome 6p21.1
(Radaev et al., 2003; Kelker et al., 2004b) and cluster with the
related NKp44 receptor (Allcock et al., 2003). Several related
receptors, such as the TREM-like transcripts (TLT) 1-5 also map
to this region of the human genome and share the V-domain
of the Ig superfamily but unlike TREM, they also contain an
immunoreceptor tyrosine inhibitory motif in their cytoplas-
mic tail (Allcock et al., 2003). In the laboratory mouse, the
TREM genes map to chromosome 17C3 (Chung et al., 2002;
Watarai et al., 2008; Paradowska-Gorycka and Jurkowska, 2013).
TREM-3, which is not found in humans and shares 43% sequence
similarity with TREM-1, is located directly next to TREM-1 in
the mouse genome, and is predicted to be functionally similar
to TREM-1 (Chung et al., 2002; Radaev et al., 2003). pDC-
TREM (also called TREM-4 and not expressed in human cells)
is present on mature mouse plasmacytoid dendritic cells (pDCs)
and share ∼20% amino acid homology with TREM-1 and
TREM-2 (Watarai et al., 2008). Two independent groups have
solved the structure of the extracellular IgV domain of TREM-1.
Although, the results have been conflicting, both groups have val-
idated that TREM-1 belongs to the Ig superfamily (Radaev et al.,
2003; Kelker et al., 2004a,b).
CELLULAR LOCALIZATION
TREM-1 and TREM-2 were first identified on lipopolysaccharide
(LPS)-stimulated monocytes and neutrophils (Bouchon et al.,
2000), following which the initial search for TREMs was mostly
limited to immune cells. The types of human immune cells
expressing high levels of TREM-1 includes monocytes, neu-
trophils, granulocytes, DCs and natural killer (NK) cells, and low
level expression on T cells and all subsets of B cells (Allcock et al.,
2003; Matesanz-Isabel et al., 2011; Rigo et al., 2011). However,
more recent studies have characterized the expression of TREM
family members in several human and mouse non-immune cells
and tissues. Studies describing the presence of TREMs in dif-
ferent cell types and species are summarized in Table 1. The
presence of TREM-1 is now reported in varying human and
mouse non-immune cells such as epithelial cells and fibroblasts,
and in tissues such as lymph nodes, spinal cord, lung, heart, and
placenta (Gingras et al., 2002; Chen et al., 2008; Wu et al., 2012;
Zangi et al., 2012). TREM-2 has the widest range of expression
so far and includes myeloid cells, osteoclasts and microglia, and
tissues such as kidney, liver, heart, brain, and lung (Schmid et al.,
2002; Paloneva et al., 2003). As seen in Table 1, the literature on
the expression patterns of other TREM and TLT family members
is limited and mostly reports presence on mouse immune cells.
However, this expanding list of cell types and species is likely to
continue growing as further research on TREMs is undertaken.
SOLUBLE TREM AS MARKER OF DISEASE SEVERITY
Although TREM family members are typically membrane-bound
receptors, multiple members are now reported to exist in a soluble
form in the clinical samples of patients from several inflammatory
conditions. So far, soluble forms of TREM-1, TREM-2, and TLT-1
have been identified (Klesney-Tait et al., 2006). However, it is pos-
sible that other members of the family might also be recognized
in this form. The soluble form of TREM-1, a 27 kDa glycosylated
peptide, is most likely produced by the cleavage of the extra-
cellular ectodomain of the membrane-bound form by matrix
metalloproteinases (Gómez-Piña et al., 2007). Using in vitro time-
course analysis, Gómez-Piña and colleagues demonstrated that
increased levels of sTREM-1 correlated with decreased cell sur-
face TREM-1 expression after 6 h of LPS stimulation of CD14+
monocytes (Gómez-Piña et al., 2007). It remains probable, how-
ever, that sTREM-1may be produced through alternate pathways,
such as alternate spicing (Gingras et al., 2002).
In clinical conditions, sTREMwas first identified in the plasma
of patients with sepsis (Gibot et al., 2004c) and in bronchial lavage
specimens of pneumonia patients (Gibot et al., 2004a). Elevated
levels of sTREM-1 have now been found in multiple infectious
and chronic inflammatory diseases such as pneumonia, pleural
effusion, intra-abdominal infections, inflammatory bowel dis-
orders, inflammatory rheumatoid disorders, and lung cancer as
reviewed previously (Barraud and Gibot, 2011). In addition to
the serum, two studies reported increased sTREM-1 levels in cere-
bral spinal fluid (CSF) of bacterial meningitis patients implying
that it may be a marker of differentiating bacterial vs. non-
bacterial meningitis (Determann et al., 2006; Bishara et al., 2007).
Although the sample size of non-bacterial cases was very small as
compared to bacterial meningitis cases, nonetheless, these stud-
ies emphasize that TREM-1 signaling may be modulated during
CNS infections. Initial interpretations of these data led to the pro-
posal of developing sTREM-1 as a biomarker for the diagnosis
of acute inflammatory diseases, such as septic shock. However,
this observation was not supported by subsequent studies and is
now considered as a possible indicator of increased severity of the
disease (Determann et al., 2006; Bucova et al., 2012). At present,
the function of sTREM is unknown, but based on the data on
other soluble forms of membrane receptors such as ICAM-1 and
VCAM-1 (Page and Liles, 2013), it is possible that sTREM-1 and
sTREM-2 may negatively regulate TREM receptor signaling via
neutralization of the respective ligands.
TREM LIGANDS
Identification of the ligands for any receptor is a crucial step
in establishing a link between a signaling receptor and disease
pathogenesis. The search for TREM family ligands has been elu-
sive, although multiple putative ligands have been proposed.
Haselmayer and co-workers identified a membrane-bound ligand
for TREM-1 on the surface of platelets, which upon interact-
ing with TREM-1, amplified LPS-induced neutrophil activation
(Haselmayer et al., 2007). Evidence for the presence of a soluble
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Table 1 | Cellular expression profiles of the TREM family proteins.
Cell type/tissue Species References
TREM-1
Neutrophils, CD14high Monocytes Human Bouchon et al., 2000
NK cell line, fibrosarcoma (HT1080) Human Allcock et al., 2003
Differentiated U937 cells Human Gingras et al., 2002
Lymph nodes, placenta, spinal cord, lung, spleen, and heart tissues Human Gingras et al., 2002
High expression: Monocytes, granulocytes, DCs, NK cell Human Matesanz-Isabel et al., 2011
Low expression: T cells and all subsets of B cells except plasma cells
Normal bronchial epithelial cells Human Rigo et al., 2011
Myofibroblasts and primary hepatic stellate cells Human Liao et al., 2012
Gastric epithelial cell lines Human Schmaußer et al., 2008
Liver endothelial cells Mouse Chen et al., 2008
Kupfer cells and neutrophils Mouse Wu et al., 2012
Peritoneal macrophages Mouse Bouchon et al., 2001a
Immature dendritic cells Mouse Zangi et al., 2012
TREM-2
Monocyte derived dendritic cells Human Bouchon et al., 2001a
NK cell line, fibrosarcoma (HT1080), U937, and THP-l Human Allcock et al., 2003
Activated macrophages, peritoneal macrophages, RAW264 cells Mouse Turnbull et al., 2006
Ostoclasts Human Paloneva et al., 2003
Microglia Mouse Schmid et al., 2002
High expression in CNS, heart and lungs as compared to lymph nodes, kidney, liver, and testes Mouse Schmid et al., 2002
TREM-3
RAW264, MT2 macrophage cell lines, and T cell lines Mouse Chung et al., 2002
pDC-TREM (TREM-4)
pDCs (CD11cdull population) Mouse Watarai et al., 2008
TLT-1
Platelets and megakaryocytes Mouse Washington et al., 2004
TLT-2
B cells, neutrophils, and macrophages Mouse King et al., 2006
ligand for TREM-1 comes from a study showing that exposure
of human monocytes to the serum of septic patients and LPS
increased production of tumor necrosis factor-α (TNF-α), which
was blocked by TREM-1/Fc fusion peptide (Wong-Baeza et al.,
2006). Moreover, a few DAMPs and PAMP are described as possi-
ble TREM-1 ligands, indicating that TREM-1 could act as a PRR
in a similar capacity as TLRs.Mohamadzadeh and colleagues used
a viral replicon system to demonstrate that the surface glyco-
protein, but not the nuclear protein, of Marburg virus was able
to bind to a TREM-1/Fc fusion peptide (Mohamadzadeh et al.,
2006). In the list of potential DAMPs, two independent studies
have proposed high-mobility group box 1 protein (HMGB1) or
heat shock protein 70 (HSP70) as possible ligands for TREM-1 (El
Mezayen et al., 2007;Wu et al., 2012). HMGB1 andHSP70 present
in the necrotic cell lysates of myeloid cells were responsible for sig-
nificant induction of the proinflammatory cytokine expression,
which was reduced by blocking TREM-1, thus confirming the role
of TREM-1 in cytokine expression cascade via responding to these
endogenous DAMPs. Collectively, these data suggest that TREM-
1 may not have a single ligand, as most activating receptors do,
but might recognize multiple epitopes and bind to a range of viral
ligands.
TREM-1 SIGNALING AND INFLAMMATION
Activation of TREM-1 signaling is initiated upon binding of the
ligand to the receptor, which triggers the association and phos-
phorylation of immunoreceptor tyrosine-based activation motif
of the adaptor protein DAP12. The signaling pathways triggered
downstream to DAP12 phosphorylation are very specific to the
TREM family member. In vitro studies in relevant cell types such
as neutrophils and macrophages demonstrate that phosphoryla-
tion of DAP12 by Src family kinases results in the recruitment and
activation of non-receptor tyrosine kinase Syk. The Syk, in turn,
activates the downstream signaling molecules including PI3K,
PLCγ, ERK1/2, and MAP kinases that regulate NF-κB activation
and expression of inflammatory genes in a cell-specific manner
(Bouchon et al., 2000; Tessarz and Cerwenka, 2008; Ford and
McVicar, 2009). Although the exact pathway remains unclear,
TREM-1 signaling via phosphorylation of Syk also regulates cal-
cium influx, which further activates MAPK/ERK pathway (Arts
et al., 2013). In neutrophils, TREM-1 also regulates neutrophil
degranulation and production of reactive oxygen species in addi-
tion to cytokines and chemokines (Bouchon et al., 2001a; Radsak
et al., 2004; Haselmayer et al., 2007) On the other hand, activation
of DAP12 by TREM-2 is shown to promote anti-inflammatory
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response in a cell-specific manner (Paradowska-Gorycka and
Jurkowska, 2013). In contrast to TREM-1, TREM-2 signaling does
not involve NF-κB translocation and is shown to induce DAP12-
dependent calcium influx followed by activation of ERK and
PI3K (Bouchon et al., 2001b). Although the overlap and cross-
talk between TREM-1 and TREM-2 signaling pathway is not yet
clear, several studies demonstrating downregulation of cytokines
such as TNF-α by TREM-2 (Takahashi et al., 2005) emphasize
opposing physiological roles of these two receptors.
Amplification of inflammation is the best-characterized func-
tion attributed to TREM-1. Because of the absence of a well-
characterized ligand, an agonist antibody to TREM-1 is routinely
used to over activate TREM-1 signaling. Bouchon and colleagues
first showed that the key functional outcome of the artificial over-
activation of TREM-1 receptor in monocytes was the increased
production of cytokines, such as TNF-α, monocyte chemoattrac-
tant protein 1 (MCP-1) and interleukin-1β (IL-1β) following LPS
treatment (Bouchon et al., 2000). Following this observation,
several studies demonstrated the ability of TREM-1 to amplify
inflammation during septic shock. Pharmacological inhibition
of TREM-1 by the use of synthetic peptides or fusion protein
repeatedly prevented hyper-responsiveness and death during var-
ious experimental septic shock models: endotoxemia in mice or
monkeys (Bouchon et al., 2001a; Derive et al., 2014), bacterial
pneumonia in rats (Gibot et al., 2006), polymicrobial peritoni-
tis in rodents and pigs (Gibot et al., 2004b; Derive et al., 2013).
By contrast, genetic invalidation of TREM-1 leads to contrast-
ing results: while some report a decreased bacterial clearance
and survival during Pneumococcal pneumonia and Klebsiella
pneumonia liver abscesses in mice (Hommes et al., 2014; Lin
et al., 2014), the opposite has been described in the setting
of Leishmania major infection (Weber et al., 2014). Further,
using siRNA silencing of TREM-1 in the mouse, Gibot and col-
leagues demonstrated the importance of the balanced activation
of TREM-1 signaling during sepsis. This study showed that par-
tial silencing of TREM-1 was protective during peritonitis, while
complete silencing was lethal to septic mice (Gibot et al., 2007).
This effect of TREM-1-dependent enhancement of inflamma-
tory response is also observed in non-infectious disease models
including hemorrhagic shock and pancreatitis (acute inflamma-
tion) and chronic inflammatory bowel diseases and inflammatory
arthritis (Barraud and Gibot, 2011). TREM-1-deficient mice dis-
played significantly attenuated disease that was associated with
reduced inflammatory infiltrates and diminished expression of
pro-inflammatory cytokines, thus representing an attractive tar-
get for treatment of chronic inflammatory disorders (Weber et al.,
2014). Such data are significant in suggesting that TREM-1 is not
simply an inflammatory amplifier, but also plays a regulatory role
in influencing the disease outcome.
It is now established that for the culmination of balanced and
effective innate immunity, it is crucial to have crosstalk between
multiple innate immune signaling pathways. Many recent studies
support a model of synergy between TREM-1 and other PRRs,
although the precise mechanisms are yet unclear. Available data
indicates that the synergy between TLRs and TREMs might be
at two levels. First, is the ability of TLR ligands to increase the
mRNA expression of TREM-1, and second, the amplification of
TLR-induced inflammatory response by TREM-1. Exposure of
immune cells to several PAMPs, such as LPS (a TLR-4 ligand)
and lipoteichoic acid (a TLR-2 ligand), and microbial pathogens
such as Pseudomonas aeruginosa have shown to increase TREM-1
mRNA (Bleharski et al., 2003; Zeng et al., 2007; Zheng et al.,
2010). In a TLR-2 dependent manner, soluble fungal antigens
were shown to up-regulate the expression of TREM-1 transcripts
in macrophages (Buckland et al., 2011). Similarly, expression of
TREM-1 mRNA following activation of macrophages by LPS was
dependent on the TLR-4/NF-κB pathway (Zeng et al., 2007).
The reverse was not true, TREM-1 signaling had no effect on
TLR-4 expression. The mechanisms by which TREM-1 amplifies
TLR-initiated inflammation are still being investigated. However,
available data suggest that the synergy is at the level of NF-κB
and IRAK-1 and appears to be cell-specific (Arts et al., 2013).
Activation of TREM-1 using agonistic monoclonal antibody in
combination with the ligands for TLR-4 was shown to syner-
gistically amplify the production of proinflammatory cytokines
in monocytes (Bouchon et al., 2000). More recent studies by
Ornatowska and colleagues used pathway-specific microarray
analysis to show that TREM-1 silencing did not alter expression of
TLR-4, but reduced the expression of adaptor protein Myd88 and
cytokines such as IL-1b and IL-10, thus emphasizing that regu-
lating expression of downstream signaling molecules may be one
of the mechanisms of TREM-1/TLR cross talk (Ornatowska et al.,
2007). Likewise, Hu and group further support the role of MyD88
protein as the point of cross talk between TREM-1 and TLR-
4 signaling in the infection of corneal epithelial cells with fungi
Aspergillus fumigatus (Hu et al., 2014). Additionally, artificial acti-
vation of TREM-1 is also shown to down-regulate expression of
Tollip and ST2, negative regulators of TLR-2 and TLR-4 path-
ways (Lagler et al., 2009;Wu et al., 2011) These studies collectively
emphasize the fact that cross talk between TLRs and TREM-1 is
at multiple levels.
Most of the TREM research so far has focused on non-viral
infections and autoimmune diseases. However, characterization
of several additional roles of TREM-1 such as modulation
of T-cell proliferation and APC activation clearly argues for its
crucial immunomodulatory role in virus infections. Below we
present essential elements of antiviral immune responses and
then discuss how TREM-1 signaling fits into these immune events
based on the current literature on TREMs in innate-adaptive
interface.
ANTIVIRAL IMMUNITY
Immune responses to virus infections are as diverse and com-
plex as the viruses that induce them. However, there are specific
events shared by many viruses, which are important determi-
nants of virus clearance vs. immunopathology. An important
feature of an efficient innate response to the entry of both DNA
viruses, such as herpes simplex virus and cytomegalovirus, and
RNA viruses, including Influenza A virus, West Nile virus (WNV)
and chikungunya virus (CHIKV), is the rapid detection by PRRs,
notably endosomal TLRs (TLR-3, TLR-7/8 and TLR-9), RLRs
(RIG-I and MDA5) and the NLRs (NLRP3 and NOD2) (Lund
et al., 2004; Wang et al., 2004; Varani et al., 2007; Zhang et al.,
2007; Daffis et al., 2008; Kumar et al., 2013). The production of
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inflammatory cytokines is one of the hallmarks of PRR activation
in innate immune cells including dendritic cells (DCs), and is
required for the recruitment and activation of inflammatory cells
such as macrophages, NK cells and neutrophils to the site of
infection (Saitoh et al., 2012; Jenne et al., 2013). The profile of
cytokines produced by innate immune cells dictates the adaptive
immune response and the virus disease outcome. Unlike bacte-
rial infections, another major innate immune response to virus
infection is the production of type I IFN. The paracrine and
autocrine secretion of IFN renders cells “antiviral” by inducing
several interferon-stimulated genes (ISGs). These ISGs confer an
antiviral state by blocking virus replication at different levels such
as early-stage virus infection, inhibition of post-transcriptional
modification and virus maturation, activation of macrophages
and DC and stimulation of NK cells to kill virus-infected cells.
As an immediate effect of innate immune activation, effec-
tor cells such as NK cells and CD8+ T cells are recruited at the
site of infection. These cells act to kill virus-infected cells and
macrophages clear the resulting debris. Further, depending on the
cytokines induced by the APCs, different types of T helper cell
responses are induced. Recruited CD4+ T cells progress toward a
TH1 phenotype in most viral infections, eventually leading to the
induction of several components of adaptive immunity. However,
viruses such as human immunodeficiency virus type 1 (HIV-1),
HSV and hepatitis C virus (HCV) also drive TH17 and T regu-
latory cells (TREG) cell expansion (Rouse and Sehrawat, 2010).
Influenza virus is another example where TH17 cell responses
mediate recruitment of neutrophils, which then become respon-
sible for the associated lung pathology (Bermejo-Martin et al.,
2009). Humoral immunity provided by specific neutralizing anti-
bodies is also an essential component of the adaptive immune
response to virus infection that inhibits virus attachment, inter-
nalization and protection against subsequent infection. At the
later stages of infection, resolution of inflammation and the
return to homeostasis is mediated by anti-inflammatory com-
ponents, classically TREG and the cytokines IL-10 and TGF-β,
to prevent tissue damage after virus clearance. Viruses, such as
HSV, HCV, and HIV use the strategy of increased TREG functions
to facilitate persistent infection (Veiga-Parga et al., 2013). Thus,
induction of an effective and balanced innate immune response
is an important determinant of virus disease outcome and is
fine-tuned by multiple immune components. Understanding the
specific mechanisms associated with the fine control of innate
immune signaling pathways has been greatly enhanced because
of the identification of several novel host molecules involved
with either blocking or facilitating the synergy between important
immune signaling pathways. TREMs family of proteins represents
this class of novel innate immune molecules, which can influence
the innate immune responses to viruses. The potential roles of
TREM-1 in the different arms of viral immunity are discussed in
the sections below.
ACTIVATION OF TREM-1 SIGNALING BY VIRUSES
In 2006, Mohamadzadeh and colleagues first reported acti-
vation of TREM-1 signaling in filovirus-infected neutrophils.
Although Marburg and Ebola viruses do not replicate in pri-
mary human neutrophils, they increased TREM-1 expression
following internalization, which correlated with phosphorylation
of DAP12 and ERK1/2. Additionally, this study also suggested that
the surface glycoprotein (GP) of filoviruses may act as a ligand
for TREM-1 (Mohamadzadeh et al., 2006). In the clinical sce-
nario, increase in the neutrophils has been reported during the
human Ebola disease (Martini, 1973; Fisher-Hoch et al., 1985).
Further, in vitro studies have demonstrated that the soluble vari-
ant of Ebola GP can interact with neutrophils (Yang et al., 1998).
Therefore, it is possible that the interaction between TREM-1
on neutrophils with the GP protein during infection contributes
to the “cytokine storm” associated with lethal filovirus disease
(Wauquier et al., 2010). Similarly, exposure of PBMC to the
gp41 protein of HIV-1 has been shown to up-regulate the mRNA
expression of TREM-1 (Denner et al., 2013). Another recent study
by Suthar and co-workers used transcriptional profiling and path-
way modeling to show that TREM-1 signaling was enriched in
the liver following infection with WNV in mice (Suthar et al.,
2013). Although this study implies that TREM-1 signaling might
be one of the pathways responsible for restricting tissue tropism,
the precise role of TREM-1 in WNV pathogenesis has not been
explored.
However, indirect evidence supports the ability of viruses to
induce TREMs. Bleharski and colleagues first showed that poly
(I:C), a ligand for TLR-3, can induce the transcription of TREM-
1 in primary monocytes (Bleharski et al., 2003). Later, studies by
Begum and co-workers could not validate the increase of TREM-1
mRNA following stimulation of monocytes with poly (I:C), how-
ever the reason for this discrepancy might be the different time
points of analysis, 6 h after stimulation, as compared to 24 h time
point used in the previous study (Begum et al., 2004). Watarai
and colleagues demonstrated that TREM-4 mRNA expression
increased in mouse pDCs following TLR-7 or -9 activation and
led to DAP12-phosphorylation, activation of ERK1/2 signaling
and ultimately IFN-α secretion (Watarai et al., 2008). Although
such studies are limited, they strongly suggest that diverse RNA
and DNA viruses that produce poly (I:C) and CpG DNA may be
capable of inducing TREMs.
Similarly, our understanding of whether viruses can induce
production of sTREM-1 is unclear and so far comes from only one
clinical study. Ruiz in-Pacheco and colleagues recently demon-
strated increased levels of sTREM-1 in the serum of dengue virus
(DENV)-infected patients during the early stages of infection
(first 5 days) as compared to healthy individuals (Ruiz-Pacheco
et al., 2014). At this point, one can only speculate the role of
sTREM in pathogenesis of DENV, an important global human
pathogen, however, this is an important finding and provides
direct evidence of modulation of TREM-1 in response to virus
infection. Elevated levels of sTREMs could signify either a virus-
induced compensatory mechanism to counteract inflammatory
process, or a host-induced mechanism to control tissue dam-
age by attenuating downstream inflammatory signals. Therefore,
such clinical studies will be highly relevant to identify the poten-
tial of sTREM-1 as a marker of disease severity in acute virus
infections as with influenza virus and CHIKV.
IMPACT OF TREM-1 ON VIRUS-ASSOCIATED
INFLAMMATION
The function of TREM-1 in modulating virus-associated inflam-
mation appears to be supported more by in vitro studies using
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FIGURE 1 | The putative interactions between viruses and TREM-1
signaling. During early stages of infection, viral nucleic acids and some
proteins are detected by TLR-3, TLR-7/8 and TLR-9, which induce the mRNA
production of pro-inflammatory cytokines, chemokines, and cell surface
receptors including TREM-1. Viruses shown to increase TREM-1 mRNA
and/or soluble TREM-1 levels are depicted in red, although the associated
pathways are not clear. Increased TREM-1 receptor responds to yet
uncharacterized viral or putative host ligands and activates signaling via
DAP12 and Syk tyrosine kinase. Downstream PI3K and ERK signaling further
activate NF-κB and synergizes with the TLR cascade to amplify inflammation.
The potential interactions between virus-induced TREM-1 and other cellular
pathways such as type I IFN and apoptosis are not yet defined.
viral PAMPs, than actual virus infections (Figure 1). Activation
of TREM-1 by TLR-9 ligand CpG DNA enhanced TNF-α pro-
duction in mouse bone marrow-derived dendritic cells (BMDCs)
(Hara et al., 2007). Similarly, Netea and colleagues noted
increased production of TNF-α in TREM-1-activated human
PBMC following stimulation with poly (I:C) and CpG (Netea
et al., 2006). This was also the first study to indicate that TREM-1
synergizes with NLR pathways. NLR ligands amplified the pro-
duction of TNF-α, IL-1β, and IL-6 when TREM-1 signaling was
activated (Netea et al., 2006). Similarly, TLR-TREM synergistic
activation of neutrophils is not restricted to TLR-2 and TLR-4
but also occurs with TLR-7 and TLR-8, which are common TLRs
responding to virus PAMPs (Radsak et al., 2004). Filoviruses are
the only viruses, where the function of TREM-1 in regulating
production of pro-inflammatory cytokines such as TNF-α and
IL-1β is documented (Mohamadzadeh et al., 2006). The impact of
TREM-1 in regulating inflammation in other virus diseases awaits
discovery. Comprehensive analysis of virus infections in vitro as
well as in TREM-1 deficient mice will be required before we fully
understand the cooperation between TREM-1 and other viral
PRRs in the context of the virus-associated inflammation.
MODULATION OF TYPE I IFN BY TREM-1
The ability of the innate immune cells to rapidly produce type
I IFN is one of the major determinants of the virus disease
outcome. However, its role in other non-viral disease models,
including bacterial infections, shock, and autoimmunity is less
well-defined and complicated. With the emphasis of TREM-1
studies mainly in bacterial infection models, the role of TREM-
1 in the regulation of type I IFNs has not been investigated so far.
However, other TREMmembers have been shown to positively or
negatively regulate type I IFN responses. In plasmacytoid DCs,
stimulation of TREM-4 resulted in increased IFN-α secretion,
and was dependent on the phosphorylation of DAP12 and PI3K
and ERK1/2 pathways (Watarai et al., 2008). Conversely, mouse
BMDCs deficient in TREM-2 had increased transcriptional lev-
els of type I IFN following TLR-9 activation (Ito and Hamerman,
2012). Therefore, the fact that TREM-1 can synergize with TLR-
3 and TLR-7 and signal through the ERK1/2 pathway leads us to
speculate that TREM-1 might play a role in positively regulating
type I IFN levels.
ROLE OF TREM-1 IN APC ACTIVATION, MIGRATION, AND
T-CELL PRIMING
The availability of recently developed TREM-1-deficient mice
have led to studies describing several novel functions of TREM
family members in addition to amplifying inflammation. Wu
and colleagues developed a TREM-1 knockout (KO) mouse
and demonstrated that TREM-1 was essential for the acti-
vation of Kupffer cells in the diethylnitrosamine model of
hepatocellular carcinoma and contributed to chronic liver dam-
age. TREM-1 KO macrophages were not as responsive as WT
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to signals from necrotic hepatocytes and exhibited attenuated
APC responses including reduced production of IL-1β, IL-6,
TNF-α, and CCL2 (Wu et al., 2012). In line with this, the role
of TREM-1 in leukocyte recruitment is clearly demonstrated
by Klesney-Tait and co-workers who used a double knockout
TREM-1/3 mice for Pseudomons aeruginosa infection (Klesney-
Tait et al., 2012). TREM-1/3 deficiency increased mortality of
infected mice, which correlated with higher local and systemic
cytokine production. However, although TREM-1/3-deficient
neutrophils had intact bacterial killing and chemotaxis proper-
ties, histologic examination of TREM-1/3-deficient lungs revealed
decreased neutrophil infiltration of the airways (Klesney-Tait
et al., 2012).
Another novel function attributed to TREM-1 recently is
its ability to influence the differentiation of primary mono-
cytes into immature DCs. TREM-1 governs the upregula-
tion of the surface expression of CD86 and MHC class II,
rendering them more efficient at eliciting T-cell prolifera-
tive activity (Bleharski et al., 2003). Likewise, it has been
demonstrated that signaling through TREM-1 on hypoxic
iDCs up-regulates T cell co-stimulatory molecules, includ-
ing CD83, CD86, and HLA-DR. Co-culture of these hypoxic
iDCs with T-cells resulted in increased the cell proliferation
and IFN-γ and IL-17 production (Pierobon et al., 2013).
However, alternatively, Ito and Hamerman used TREM-2 defi-
cient BMDCs to demonstrate that TREM-2 inhibited TLR-
induced DC maturation and antigen presentation to T cells (Ito
and Hamerman, 2012) thus supporting the dynamic opposite
roles of TREM-1 and TREM-2 at the level of antigen presentation
as well.
APC activation is essential during virus infection for the stim-
ulation of TH1 responses and subsequent development of neutral-
izing antibodies vital for viral clearance. In addition to APC acti-
vation, TREM signaling also can skew T-cell responses in a TH1 or
TH17 direction. Pierbon and colleagues, for instance showed that
TREM-1 signaling in hypoxic iDCs was responsible for TH1/TH17
priming (Pierobon et al., 2013), while two independent stud-
ies showed a reduction in systemic TH1 responses following
inhibition of TREM-1. In a model of Pseudomonas aeruginosa-
induced keratitis, inhibition of TREM-1 reduced IFN-γ responses
(TH1 phenotype), while increasing TH2 cytokines including IL-
4 and -5 (Wu et al., 2011). Similar results were obtained in
a model of cardiac allografts, in which TREM-1 inhibition led
to increased allograft survival by dampening the differentiation
and proliferation of IFN-γ secreting CD4+ T cells (Schiechl
et al., 2013). In addition, TREM-1 signaling can be influenced
by a TH1 environment; treatment of primary human NK cells
with the classic TH1 cytokines IL-12 and -18 led to the acti-
vation of TREM-1 signaling events, as measured by microarray
analysis (Grangeiro de Carvalho et al., 2011). Currently, there
is no evidence supporting the hypothesis that TREM-1 may
modulate innate-adaptive immune interface in virus infections.
However, because viral ligands can activate TREM-1 signal-
ing and cytokines production, there is high likely hood that
cytokines governed by TREM-1may influence activation of APCs,
which in turn may impact protective T-cell functions and viral
clearance.
RETURN TO HOMEOSTASIS
Anti-inflammatory reactions are important in any immune reac-
tion to return the host to homeostasis. In virus infections, one
of the factors that determine the balance between virus clearance
and tissue damage is the timely induction of anti-inflammatory
molecules. Available data indicate that TGF-β and IL-10 treat-
ment of primary monocytes synergistically down-regulates cell
surface expression of TREM-1 (Schenk et al., 2005), but whether
TREM-1 signaling can influence production of TGF-β and IL-10
has not been clearly defined. Nonetheless, this study strongly sup-
ports the notion that TREM-1 is the target of anti-inflammatory
cytokines and that attenuating TREM-1- associated information
might be one of the events in the immune homeostasis pro-
cess. In microglia, TREM-2 participates in the process of tissue
debris clearance and resolution of latent inflammatory reactions
in Nasu-Hakola disease, a recessively inherited chronic neurode-
generative disease (Colonna, 2003). Similar anti-inflammatory
and protective functions of TREM-2 have been proposed for
other acute neuroinflammatory diseases, such as multiple scle-
rosis (Piccio et al., 2007) and Alzheimer’s disease (Guerreiro
et al., 2013; Jonsson et al., 2013), implying that alterations in
the immune homeostasis may be mediated by TREMs in infec-
tions with neurotropic viruses, such as HIV, WNV or tick-borne
encephalitis virus (TBEV).
CONCLUSIONS AND FUTURE PERSPECTIVES
The immune functions of the TREM family are broad and diverse
(Table 2) and may contribute to antiviral immunity. One of
the pertinent questions is, can TREM-1 signaling respond to
infection with globally important human viruses? Of particular
interest would be the viruses associated with acute inflamma-
tion as the major cause of pathology such as orthomyxoviruses
(influenza virus), filoviruses (Ebola and Marburg viruses), fla-
viviruses (DENV, WNV, and TBEV) and alphaviruses (CHIKV).
More importantly, it is essential to characterize the role of TREM-
1-dependent responses in disease outcome, i.e., protective vs.
pathogenic. For example, it is likely that TREM-1 signaling
may promote inflammation and cause substantial tissue damage
thereby contributing to disease pathogenesis of acute infections
as with influenza virus or CHIKV. In this regard, Weber and
colleagues recently demonstrated that TREM-1 deficient mice
were protected from severe influenza disease without affecting
virus clearance, although this study did not look into the innate
immune markers governed by TREM-1 (Weber et al., 2014).
On the other hand, in virus infections with WNV, TBEV or
Japanese encephalitis virus, activation of TREM-1 might be pro-
tective and enhance the robustness of innate immune responses
in the periphery thereby facilitating efficient virus clearance and
reduced neuroinvasion. This notion is supported by our unpub-
lished data demonstrating increased mortality and morbidity in
WNV-infected TREM-1/3-deficient mice. Our unpublished data
further demonstrates that WNV can induce TREM-1 mRNA in a
cell-type specific manner.
The question of how TREM-1 might influence disease out-
come differently in acute vs. chronic infections with HIV or
HCV also remains to be explained. Identification of inflamma-
tory cytokines and chemokines regulated by TREM-1 will provide
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Table 2 | The role of the TREM family receptors in immune responses relevant to antiviral immunity.
Immune response Function of TREMs Model References
Inflammation/PRR
signaling
Exposure to Poly(I:C) up-regulates trascription of TREM-1 Human monocytes Bleharski et al., 2003; Netea
et al., 2006
TREM-1 synergizes with TLR-7/8 Neutrophils Radsak et al., 2004
TREM-1-TLR-9 (CpG) synergy amplifies TNF-α production Mouse BMDC and
human PBMC
Netea et al., 2006; Hara et al.,
2007
Crosstalk between NLR and TREM-1 signaling increases
TNF-α, IL-Iβ and IL-6 production
Human PBMC Netea et al., 2006
Type I IFN response pDC-TREM (TREM-4) contributes to IFN-α production Mouse splenocytes Watarai et al., 2008
TREM-2 has inhibitory action on type I IFN mRNA
expression
Mouse BMDC Ito and Hamerman, 2012
APC activation TREM-1 modulates iDC differentiation and induce
expression of CD1a, CD86, and HLA-DR
Human monocytes Bleharski et al., 2003
Deficiency of TREM-1 attenuates activation of Kupfer cells In vivo mouse model Wu et al., 2012
TREM-1 promotes up-regulation of T-cell co-stimulatory
molecules and production of pro-inflammatory mediators
Hypoxic iDC Pierobon et al., 2013
TREM-2 inhibits the induction of antigen-specific T-cell
migration
Mouse BMDC Ito and Hamerman, 2012
TH1 Response IL-12 and -I8 treatment can induce TRE M-1 signaling Human NK cells Grangeiro de Carvalho et al., 2011
TREM-1 promotes a TH1/TH17 response during hypoxic
conditions
Hypoxic iDC Pierobon et al., 2013
Inhibition ofTREM-1 decreases the differentiation and
proliferation of IFNγ producing CD4+ T cells
In vivo mouse model Schiechl et al., 2013
Inhibition of TREM-1 decreases TH1 responses and TLR
signaling and increases TH 2 cytokine production in
infection
In vivo mouse model of
P. Aeruginosa
Wu et al., 2011
Other elements of
viral inflammution
TREM-1 mediates LPS-induced NOS-2 expression Mouse macrophages and
endothelial cells
Chen et al., 2008
Exposure to Filoviruses led to TREM-1-dependent
production of cytokines
Human neutrophils Mohamadzadeh et al., 2006
LPS-induced production of CCL2 is dependent on TREM-1 Human monocytes Bouchon et al., 2000
Return to
homeostasis
TGF-β and IL-10 treatment down-regulates TREM-1
expression
Human monocytes Schenk et al., 2005
valuable insights into the role of TREM-1 in APC activation,
T-cell responses and anti-viral immunity. Further, given that the
type I IFN system is a powerful line of defense, characterization
of the function of TREM-1 in modulating IFN levels and devel-
opment of effective neutralizing antibody responses will further
enhance our understanding of the complex network of antiviral
immunity and fine-tuning of adaptive immunity.
In conclusion, this review describes the possible roles TREM-
1 might play during virus infections. Future research using
newly developed TREM-1 knockout mice and clinical samples
from infected patients should focus on assigning protective or
pathogenic functions for different viruses, examining the under-
lying cell- and tissue-type specific mechanisms of action, and
identification of potential ligands responsible for TREM-1 recep-
tor activation. There is such a large impact of the innate immune
responses on the outcome of various viral diseases, therefore
knowledge of the interactions between TREM-1 and viral PRRs
(TLRs, NLRs, and RLRs) may lead to a better understanding
of the pathophysiology of viral diseases. Further advancement
in this field is crucial before TREM-1 can be proposed as an
immunotherapeutic target to ultimately promote virus clearance
with minimum tissue damage.
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